Observational Study of Pts w/ R/R DLBCL 2nd or 3rd-Line Therapy & Not Receiving ASCT

Cancer
Elizabeth A Brem
realMIND: A multicenter, observational study to characterize the safety and effectiveness of tafasitamab in combination with lenalidomide in US patients with relapsed or refractory diffuse large B-cell lymphoma with a focus on racial and ethnic minority patients
Non-Hodgkin's Lymphoma

Study Description

The realMIND study is a multicenter, observational study intended to further characterize the safety and effectiveness data of US patients (with a focus on racial and ethnic minority patients) with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), treated with tafasitamab in combination with lenalidomide.

Eligibility

AM I ELIGIBLE TO PARTICIPATE IN THIS STUDY?

Please note this may not be a complete list of eligibility criteria. We have included a few examples of study criteria to help you better understand how your eligibility in the study will be determined; your study team will go through the study eligibility criteria with you to verify if you qualify for participation in this study.

Inclusion Requirements

You can participate in this study if you are age ≥18 years at the time of diagnosis

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.